Immunity, age, and luminal breast cancer: understanding the Holy Trinity.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41855142.
- Also identified by DOI 10.1158/1078-0432.CCR-25-4035.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In 390 patients with stage I-III hormone-receptor positive/HER2-negative breast tumors higher number of Tumor Infiltrating Lymphocytes (TILs)-subtypes, regardless of whether they were immunostimulatory or immunosuppressive, including T-regulatory cells and CD8- and non-CD8 T-cells, are associated with improved distant disease free survival and overall survival at 8 years follow-up.